Urology
Volume 69, Issue 3 , Pages 515-519 , March 2007

Prediagnostic Prostate-Specific Antigen Velocity and Probability of Detecting High-Grade Prostate Cancer

  • Stephanie C. Krejcarek

      Affiliations

    • Department of Radiation Oncology, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts
    • Corresponding Author InformationReprint requests: Stephanie Krejcarek, Brigham and Women’s Hospital, Department of Radiation Oncology, 75 Francis Street, Boston, MA 02115.
    • ,
  • Ming-Hui Chen

      Affiliations

    • Department of Statistics, University of Connecticut, Storrs, Connecticut
    • ,
  • Andrew A. Renshaw

      Affiliations

    • Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts
    • ,
  • Marian Loffredo

      Affiliations

    • Department of Radiation Oncology, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts
    • ,
  • Brenda Sussman

      Affiliations

    • Department of Radiation Oncology, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts
    • ,
  • Anthony V. D’Amico

      Affiliations

    • Department of Radiation Oncology, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts

Received 4 July 2006 ,Accepted 16 November 2006.

References 

  1. D’Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280:969–974
  2. Kupelian PA, Elshaikh M, Reddy CA, et al. Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: a large single-institution experience with radical prostatectomy and external-beam radiotherapy. J Clin Oncol. 2002;20:3376–3385
  3. Grossfeld GD, Latini DM, Lubeck DP, et al. Predicting disease recurrence in intermediate and high-risk patients undergoing radical prostatectomy using percent positive biopsies: results from CaPSURE. Urology. 2002;59:560–565
  4. Denham JW, Steigler A, Lamb DS, et al. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96-01 randomised controlled trial. Lancet Oncol. 2005;6:841–850
  5. D’Amico AV, Manola J, Loffredo M, et al. 6-Month androgen suppression plus radiation therapy vs. radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA. 2004;292:821–827
  6. Bolla M, Gonzalez D, Warde P, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med. 1997;337:295–300
  7. Roach M, DeSilvio M, Lawton C, et al. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol. 2003;21:1904–1911
  8. D’Amico AV, Renshaw AA, Arsenault L, et al. Clinical predictors of upgrading to Gleason grade 4 or 5 disease at radical prostatectomy: potential implications for patient selection for radiation and androgen suppression therapy. Int J Radiat Oncol Biol Phys. 1999;45:841–846
  9. Grossfeld GD, Chang JJ, Broering JM, et al. Under staging and under grading in a contemporary series of patients undergoing radical prostatectomy: results from the Cancer of the Prostate Strategic Urologic Research Endeavor database. J Urol. 2001;165:851–856
  10. King CR, McNeal JE, Gill H, et al. Reliability of small amounts of cancer in prostate biopsies to reveal pathologic grade. Urology. 2006;67:1229–1234
  11. D’Amico AV, Chen MH, Roehl KA, et al. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med. 2004;351:125–135
  12. D’Amico AV, Renshaw AA, Sussman B, et al. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA. 2005;294:440–447
  13. Greene FL American Joint Committee on Cancer and American Cancer Society. A JCC Cancer Staging Manual. New York: Springer-Verlag; 2002;
  14. Klein JP, Moeschberger ML. Survival Analysis: Techniques for Censored and Truncated Data.. New York: Springer; 1997;
  15. Agresti A. In: Categorical Data Analysis.. New York: Wiley-Interscience; 2002;p. 165–210
  16. Akaike H: Information and an extension of the maximum likelihood principle, in Petrov BN and Caski F (Eds): International Symposium on Information Theory. Budapest, Akademia Kiado, p 267–281.
  17. Bostwick DG. Gleason grading of prostatic needle biopsies: correlation with grade in 316 matched prostatectomies. Am J Surg Pathol. 1994;18:796–803
  18. Gilliland FD, Hoffman RM, Hamilton A, et al. Predicting extracapsular extension of prostate cancer in men treated with radical prostatectomy: results from the population based prostate cancer outcomes study. J Urol. 1999;162:1341–1345
  19. Cookson MS, Fleshner NE, Soloway SM, et al. Correlation between Gleason score of needle biopsy and radical prostatectomy specimen: accuracy and clinical implications. J Urol. 1997;157:559–562
  20. Pinthus JH, Witkos M, Fleshner NE, et al. Prostate cancers scored as Gleason 6 on prostate biopsy are frequently Gleason 7 tumors at radical prostatectomy: implication on outcome. J Urol. 2006;176:979–984
  21. King CR. Patterns of prostate cancer biopsy grading: trends and clinical implications. Int J Cancer. 2000;90:305–311
  22. Mian BM, Lehr DJ, Moore CK, et al. Role of prostate biopsy schemes in accurate prediction of Gleason scores. Urology. 2006;67:379–383
  23. Lee AK, Schultz D, Renshaw AA, et al. Optimizing patient selection for prostate monotherapy. Int J Radiat Oncol Biol Phys. 2001;49:673–677
  24. Thompson IM, Ankerst DP, Chi C, et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2006;98:529–534
  25. D’Amico AV, Hui-Chen M, Renshaw AA, et al. Identifying men diagnosed with clinically localized prostate cancer who are at high risk for death from prostate cancer. J Urol. 2006;176:S11–S15
  26. Tchetgen MB, Oesterling JE. The effect of prostatitis, urinary retention, ejaculation, and ambulation on the serum prostate-specific antigen concentration. Urol Clin North Am. 1997;24:283–291
  27. Rafferty B, Rigsby P, Rose M, et al. Reference reagents for prostate-specific antigen (PSA): establishment of the first international standards for free PSA and PSA (90:10). Clin Chem. 2000;46:1310–1317
  28. Chan TY, Chan DY, Stutzman KL, et al. Does increased needle biopsy sampling of the prostate detect a higher number of potentially insignificant tumors?. J Urol. 2001;166:2181–2184
  29. Vira MA, Tomaszewski JE, Hwang WT, et al. Impact of the percentage of positive biopsy cores on the further stratification of primary grade 3 and grade 4 Gleason score 7 tumors in radical prostatectomy patients. Urology. 2005;66:1015–1019

 This study was supported, in part, by an educational grant from Astra Zeneca, Inc.

PII: S0090-4295(06)02524-6

doi: 10.1016/j.urology.2006.11.009

Urology
Volume 69, Issue 3 , Pages 515-519 , March 2007

Article Tools